Famciclovir (Famvir)

Famciclovir is a systemic antiviral medication that has become an important therapeutic option for treating feline herpesvirus type 1 (FHV-1) infections in cats. Originally developed and FDA-approved for treating herpesvirus infections in humans under the brand name Famvir, famciclovir has been widely adopted in veterinary medicine for managing the various manifestations of FHV-1 disease in feline patients. The medication belongs to the nucleoside analog class of antivirals and functions as a prodrug, meaning it is converted in the body to its active form, penciclovir, which then exerts antiviral effects. Famciclovir has demonstrated significant clinical benefit in treating ocular, respiratory, and dermatologic disease attributed to herpesvirus infection in cats, making it one of the most versatile antiviral options available for feline patients.

The mechanism by which famciclovir works involves interference with viral DNA replication, preventing the herpesvirus from multiplying and spreading within the infected cat's body. After oral administration, famciclovir is absorbed from the gastrointestinal tract and undergoes metabolism to penciclovir, its active metabolite. Penciclovir is then phosphorylated within virus-infected cells, where it becomes incorporated into the viral DNA chain during replication, causing premature chain termination. This process effectively blocks the virus from creating new copies of itself, allowing the cat's immune system to better control the infection. While famciclovir cannot eliminate herpesvirus from the body or cure latent infections, it can significantly reduce viral shedding, decrease the severity of clinical signs, and help shorten the duration of active disease episodes.

Famciclovir is available in tablet form in several strengths, including 125mg, 250mg, and 500mg tablets, which allows veterinarians to select appropriate doses for cats of different sizes. For cats that cannot take tablets, compounding pharmacies can prepare liquid formulations, though the medication's intensely bitter taste can make oral suspensions challenging to administer to some patients. The oral route of administration makes famciclovir particularly valuable for treating systemic manifestations of herpesvirus disease that topical eye drops cannot address, including upper respiratory infections and herpes-associated dermatitis. At appropriate doses, famciclovir also achieves therapeutic concentrations in the tears, providing dual benefit for cats with both ocular and systemic disease.

Famciclovir has demonstrated a favorable safety profile in cats when used at appropriate doses, though it remains important to use this medication under veterinary supervision. Clinical studies have shown that the drug is generally well-tolerated, with most cats completing treatment courses without significant adverse effects. However, famciclovir is metabolized by the liver and excreted by the kidneys, so cats with impaired organ function may require dose adjustments or alternative treatments. As with all antiviral medications, famciclovir does not cure herpesvirus infection but rather controls active disease, as FHV-1 establishes permanent latency in the trigeminal ganglia of infected cats. Completing the full prescribed treatment course is essential for achieving optimal therapeutic outcomes and reducing the likelihood of disease recurrence.

The primary indication for famciclovir in cats is the treatment of clinical disease caused by feline herpesvirus type 1 (FHV-1), which represents one of the most common and important infectious diseases affecting the domestic cat population worldwide. FHV-1 is an alpha-herpesvirus that causes a range of clinical manifestations including ocular disease, upper respiratory infections, and occasionally dermatologic conditions. Famciclovir's systemic route of administration makes it particularly valuable for treating cats with multiple affected organ systems or those where topical treatments alone are insufficient. The medication has shown clinical efficacy in improving symptoms, reducing viral shedding, and helping cats recover more quickly from acute herpesvirus episodes.

Ocular disease represents one of the most common presentations of FHV-1 infection where famciclovir demonstrates significant therapeutic benefit. Herpetic conjunctivitis, characterized by inflammation, redness, and discharge from the eyes, responds well to oral famciclovir therapy. The medication achieves therapeutic concentrations in the tears when administered at appropriate doses, allowing it to directly combat viral replication at the ocular surface. Keratitis, involving inflammation and potential ulceration of the cornea, also benefits from famciclovir treatment. Cats with corneal sequestra, a condition strongly associated with herpesvirus infection where devitalized corneal tissue becomes pigmented, may receive famciclovir as part of their comprehensive treatment plan. The ability to treat ocular disease through oral medication is particularly valuable for cats that strongly resist topical eye drop administration.

Upper respiratory disease caused by FHV-1, commonly known as feline viral rhinotracheitis or a component of the cat flu complex, is another major indication for famciclovir therapy. Affected cats typically present with sneezing, nasal discharge, nasal congestion, and fever, often accompanied by lethargy and decreased appetite. The respiratory epithelium is a primary target tissue for FHV-1 replication, and systemic antiviral therapy helps control viral burden in these tissues more effectively than topical treatments can reach. Cats with chronic rhinosinusitis associated with herpesvirus may benefit from intermittent famciclovir courses during disease flare-ups. In shelter environments where respiratory infections spread rapidly among stressed cat populations, famciclovir has been evaluated for both treatment of clinical disease and reduction of viral shedding to limit transmission.

Feline herpes dermatitis represents a less common but important indication for famciclovir therapy. This condition manifests as ulcerative skin lesions, typically affecting the face and nose, that are directly caused by herpesvirus infection of the skin. Cats with eosinophilic dermatitis associated with FHV-1 may also respond to antiviral treatment. Because topical eye drops cannot address skin lesions, oral famciclovir provides an essential treatment option for these patients. Clinical reports have documented successful resolution of herpetic skin disease with famciclovir therapy, though treatment durations may be longer than for purely ocular or respiratory manifestations. Veterinary dermatologists may include famciclovir in their treatment protocols for cats with facial ulcerations where herpesvirus involvement is suspected.

Veterinarians choose famciclovir based on several factors including disease severity, affected body systems, patient compliance considerations, and response to previous treatments. Cats with moderate to severe clinical signs often benefit from systemic antiviral therapy rather than relying solely on supportive care. Those with concurrent ocular and respiratory involvement are ideal candidates since famciclovir addresses both simultaneously. When owners cannot reliably administer frequent topical eye medications, oral famciclovir provides a more practical alternative with its twice to three times daily dosing schedule. Cats that have failed to respond adequately to other treatments may show improvement with famciclovir, and some veterinary ophthalmologists consider it a first-line systemic treatment for herpetic ocular disease due to its favorable safety profile compared to other antiviral options.

The dosing protocol for famciclovir in cats has been refined through clinical research and extensive practical experience, though optimal dosing continues to be an area of ongoing investigation in veterinary medicine. Famciclovir pharmacokinetics in cats differ significantly from other species, with cats requiring substantially higher doses per kilogram of body weight to achieve therapeutic blood and tissue concentrations of the active metabolite penciclovir. The specific dose prescribed for any individual cat should be determined by a veterinarian based on the severity of clinical disease, the cat's weight and overall health status, and consideration of any concurrent conditions that might affect drug metabolism or elimination.

Current dosing recommendations for famciclovir in cats typically range from 40 to 90 milligrams per kilogram body weight, administered two to three times daily. Earlier studies suggested that a single 40mg/kg dose achieved similar peak plasma concentrations to 90mg/kg, but subsequent research demonstrated that cats receiving 90mg/kg showed significantly better clinical improvement and faster response times than those receiving lower doses. Many veterinary ophthalmologists and internists now recommend doses at the higher end of this range, particularly for moderate to severe disease. A commonly cited protocol involves 90mg/kg administered every 8 hours (three times daily) or every 12 hours (twice daily), with the more frequent dosing potentially providing better therapeutic effect for severe cases.

Treatment duration with famciclovir typically ranges from two to three weeks for acute disease episodes, though some cases may require longer therapy depending on clinical response. Cats with chronic or recurrent herpesvirus disease may need repeated treatment courses whenever flare-ups occur. The veterinarian will schedule follow-up examinations to assess response to treatment and determine when medication can be safely discontinued. Premature cessation of therapy can allow viral replication to resume and clinical signs to recur, so completing the full prescribed course is important. Some cats with severe or frequently recurring disease may require extended treatment periods, and veterinarians may recommend blood work monitoring for cats receiving famciclovir for longer than two weeks.

Famciclovir can be administered with or without food, though giving the medication with a small amount of food may help reduce gastrointestinal upset in sensitive cats. For cats that tolerate tablets, direct oral administration or hiding the tablet in a small amount of food or a pill pocket treat can be effective. The tablets should not be crushed, as the medication has an intensely bitter taste that can cause excessive salivation, head shaking, and treatment resistance. Cats that cannot take whole tablets may receive compounded liquid formulations, though the bitter taste makes these preparations challenging for some patients. Owners struggling with medication administration should consult their veterinarian for alternative strategies or formulation options.

If a dose of famciclovir is missed, owners should give it as soon as they remember unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular schedule resumed. Doubling up on doses is not recommended and will not compensate for missed doses while potentially increasing the risk of side effects. Maintaining consistent dosing intervals helps ensure steady medication levels in the body for optimal antiviral effect. Owners experiencing difficulty maintaining the dosing schedule should discuss the situation with their veterinarian, as alternative dosing frequencies might be possible depending on disease severity and response.

Completing the full prescribed course of famciclovir is essential for achieving the best therapeutic outcome and minimizing the risk of disease recurrence. Although clinical improvement may be visible within the first few days of treatment, continuing medication for the entire prescribed duration helps ensure adequate suppression of viral replication. Stopping treatment early when symptoms improve can allow the virus to rebound, potentially leading to return of clinical signs. Cat owners should maintain regular communication with their veterinarian throughout the treatment period, reporting any concerns about medication tolerance or response to therapy so that adjustments can be made if needed.

Famciclovir is generally well-tolerated by cats when used at appropriate doses for the treatment of feline herpesvirus infections. Clinical studies and extensive real-world experience have demonstrated that most cats complete their treatment courses without experiencing significant adverse effects. The medication has a considerably better safety margin in cats compared to some other antiviral agents, particularly valacyclovir (the prodrug of acyclovir), which causes serious toxicity in felines and should never be used in cats. Nevertheless, some cats may experience side effects during famciclovir therapy, and owners should be aware of what to monitor for so they can report concerns to their veterinarian promptly.

Gastrointestinal side effects represent the most commonly observed adverse reactions to famciclovir in cats. Approximately 17 percent of feline patients may experience some degree of digestive upset, which can manifest as decreased appetite, vomiting, or diarrhea. These effects are typically mild and often resolve with continued therapy or can be managed by administering the medication with food. Cats that vomit after receiving famciclovir on an empty stomach may tolerate the medication better when given with a small meal. Weight loss has been reported in some cats during treatment, which may relate to appetite suppression or the underlying disease process rather than direct medication effects. If gastrointestinal symptoms are severe or persistent, veterinary consultation is warranted to determine whether dose adjustment or alternative treatment is appropriate.

Increased thirst and urination have been reported in approximately 5 percent of cats receiving famciclovir. This polyuria and polydipsia may reflect effects on the kidneys, as famciclovir and its metabolites are eliminated through renal excretion. In most cases, these changes are mild and reversible upon discontinuation of treatment. However, cats that develop significant polydipsia during famciclovir therapy should be evaluated for underlying kidney function, particularly if they are older or have known risk factors for renal disease. One case report documented a cat that developed persistent low urine specific gravity following famciclovir treatment, suggesting that pre-existing subclinical kidney disease may be unmasked or exacerbated by the medication in some patients.

Other reported side effects include excessive salivation or drooling, which is primarily related to the medication's bitter taste when tablets are crushed or when compounded liquid formulations are administered. This is an aversive reaction rather than a toxic effect and can usually be managed through improved administration technique. Lethargy has been observed in some cats during treatment, though distinguishing medication effects from symptoms of the underlying illness can be challenging. Rare hematologic changes, including reductions in certain white blood cell populations, have been documented, which is why veterinarians may recommend blood work monitoring for cats receiving extended courses of famciclovir therapy.

Serious adverse reactions to famciclovir are uncommon in cats when appropriate doses are used. Owners should contact their veterinarian promptly if their cat experiences severe or persistent vomiting, complete loss of appetite lasting more than a day, significant lethargy or weakness, any signs of allergic reaction such as facial swelling or difficulty breathing, or noticeable changes in urination patterns. Cats with pre-existing kidney or liver disease are at higher risk for medication-related complications and should be monitored more closely during treatment. If side effects occur, the veterinarian can assess their severity and determine whether dose adjustment, supportive care, or treatment discontinuation is most appropriate for the individual patient.

Famciclovir should not be used in cats with known hypersensitivity or allergy to the medication or to penciclovir, its active metabolite. Although allergic reactions to famciclovir are uncommon in cats, animals that have previously experienced adverse reactions should not receive the medication again. Signs of potential allergic reaction may include facial swelling, hives, difficulty breathing, or severe skin reactions. If a cat has had reactions to related nucleoside analog antiviral medications, caution should be exercised when considering famciclovir, as cross-reactivity could potentially occur. Pet owners should inform their veterinarian of any previous medication reactions their cat has experienced before starting famciclovir therapy to ensure the safest treatment approach.

Cats with significant kidney disease require careful evaluation before famciclovir is prescribed, as the medication and its metabolites are eliminated primarily through renal excretion. Impaired kidney function can lead to accumulation of drug in the body, potentially increasing the risk of adverse effects. In human medicine, dose reductions are recommended for patients with renal insufficiency, and similar considerations apply to feline patients. Chronic kidney disease is extremely common in cats, particularly in middle-aged and older animals, making this a relevant concern for a substantial portion of the feline population. Veterinarians may recommend baseline kidney function testing before initiating famciclovir therapy in older cats or those with known risk factors for renal disease. Cats with acute kidney failure should not receive famciclovir.

Liver disease also warrants caution when considering famciclovir use, as the medication undergoes hepatic metabolism to its active form. Cats with impaired liver function may have altered drug metabolism, though specific dosing guidelines for hepatic insufficiency have not been established in cats. Severe liver disease represents a relative contraindication, and veterinarians typically consider alternative treatments for cats with significant hepatic dysfunction. If famciclovir is deemed necessary for a cat with liver disease, careful monitoring for adverse effects and potential dose adjustments may be required.

The use of famciclovir in pregnant, nursing, or breeding cats should be approached with caution due to limited safety data in these populations. While famciclovir has not demonstrated teratogenic effects in animal studies at standard doses, the potential risks to developing fetuses have not been thoroughly characterized in cats. Nursing queens present concerns about potential excretion of the medication or its metabolites into milk, which could affect nursing kittens. Cats intended for breeding programs should ideally complete reproductive activities before receiving famciclovir, or alternative treatments should be considered when antiviral therapy is needed during pregnancy or lactation. These decisions should be made carefully by the veterinarian, weighing the potential benefits of treatment against possible risks.

Pet owners should inform their veterinarian of all medications, supplements, and other treatments their cat is currently receiving before starting famciclovir therapy. Drug interactions can alter how medications work in the body, potentially reducing effectiveness or increasing the risk of adverse effects. Providing a complete medication history allows the veterinarian to anticipate potential interactions, adjust dosing schedules if needed, and monitor appropriately for any unexpected effects. This includes prescription medications, over-the-counter products, vitamins, herbal supplements, and any other substances the cat receives regularly or occasionally.

Probenecid is a medication known to interact with famciclovir and its active metabolite penciclovir. Probenecid can increase blood levels of penciclovir by interfering with its renal elimination, which could potentially enhance both therapeutic effects and risk of adverse reactions. While probenecid is not commonly used in feline medicine, veterinarians should be aware of this interaction if it is being administered for any reason. Similarly, other medications that affect renal tubular secretion could theoretically interact with famciclovir, though specific interactions have not been documented in cats. The veterinarian can evaluate potential interactions based on the cat's complete medication profile.

Concurrent use of nephrotoxic medications requires particular caution in cats receiving famciclovir, given the drug's renal elimination pathway. Medications that can affect kidney function, including certain antibiotics, nonsteroidal anti-inflammatory drugs, and some other commonly used veterinary drugs, may compound renal effects when combined with famciclovir. This is especially relevant for older cats or those with pre-existing kidney disease. Veterinarians typically monitor kidney function more closely when cats require multiple medications that could impact renal health. If nephrotoxic drugs must be used concurrently with famciclovir, dose adjustments and more frequent monitoring may be recommended.

Combination therapy with topical ophthalmic antivirals represents a common and generally acceptable practice rather than a problematic interaction. Cats with severe ocular herpesvirus disease may receive both oral famciclovir and topical cidofovir or other ophthalmic antivirals simultaneously, providing both systemic and locally concentrated antiviral activity. This combination approach is not contraindicated and may offer enhanced therapeutic benefit for cats with significant eye involvement. However, the veterinarian should coordinate all treatments and ensure that dosing schedules for multiple medications are practical for the owner to maintain. Regular follow-up allows assessment of response to combination therapy and enables adjustments as the cat's condition improves.

General precautions for using famciclovir in cats begin with ensuring accurate diagnosis and appropriate patient selection. The medication is specifically effective against herpesvirus infections and provides no benefit for diseases caused by bacteria, fungi, or other pathogens. Before initiating famciclovir therapy, veterinarians typically confirm or strongly suspect feline herpesvirus involvement based on clinical presentation, history, and potentially diagnostic testing. Starting antiviral treatment without reasonable evidence of herpetic disease can delay appropriate therapy for other conditions that may be causing the cat's symptoms. Owners should understand that famciclovir works specifically against herpesvirus and trust their veterinarian's diagnostic assessment.

Accurate weight measurement is essential for proper famciclovir dosing in cats, as the medication is prescribed based on body weight. Cats should be weighed at the veterinary clinic rather than estimated, particularly since famciclovir doses are substantially higher per kilogram than many other medications and dosing errors could affect treatment efficacy or safety. Changes in body weight during treatment may necessitate dose adjustments, and cats losing significant weight should be re-evaluated to determine whether underlying disease progression or medication effects are responsible. Maintaining awareness of the cat's weight helps ensure appropriate dosing throughout the treatment course.

Handling and administration precautions help protect both the cat and household members during famciclovir therapy. Owners should wash their hands after handling the medication and after administering doses. Pregnant women should exercise particular caution when handling famciclovir tablets, as the medication could pose risks if absorbed through skin contact. Tablets should be kept in their original packaging and stored out of reach of children and other pets. If compounded liquid formulations are used, they should be stored according to the pharmacy's instructions and administered using the provided measuring device to ensure accurate dosing.

Monitoring during famciclovir treatment helps ensure optimal outcomes and early detection of any problems. Owners should observe their cat for signs of clinical improvement, including reduced eye discharge, decreased sneezing, improved appetite, and increased energy level. Conversely, signs of worsening disease, failure to improve within a reasonable timeframe, or development of new symptoms warrant veterinary reassessment. For cats receiving extended treatment courses lasting longer than two weeks, veterinarians often recommend blood work to monitor kidney function and blood cell counts. Periodic follow-up examinations allow the veterinarian to assess treatment response and determine the appropriate duration of therapy.

Special populations require modified approaches or enhanced monitoring during famciclovir therapy. Geriatric cats commonly have concurrent chronic kidney disease, making careful attention to renal function particularly important. Kittens with developing organ systems may require veterinary guidance on appropriate dosing for their age and size. Cats with compromised immune function, whether from feline immunodeficiency virus, feline leukemia virus, or immunosuppressive medications, may experience more severe or prolonged herpesvirus infections and may need extended or repeated treatment courses. These patients benefit from close veterinary supervision and individualized treatment plans that account for their unique health circumstances.

Proper storage of famciclovir tablets ensures medication stability and therapeutic effectiveness throughout the treatment period. Commercial famciclovir tablets should be stored at controlled room temperature between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius), with brief excursions permitted to temperatures between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius). The medication should be kept in its original container with the cap tightly closed to protect against moisture and light, which can degrade the active ingredients over time. Storage locations should be away from bathrooms, kitchens, or other areas where humidity levels fluctuate, and medications should not be kept near windows or heat sources that could expose them to temperature extremes.

Compounded formulations of famciclovir require storage according to the specific instructions provided by the compounding pharmacy, which may differ from commercial tablet storage requirements. Liquid formulations may require refrigeration or may be stable at room temperature depending on the compounding base and preservatives used. Owners should carefully review the label on compounded medications and follow all storage instructions precisely. Compounded preparations typically have shorter expiration periods than commercial tablets, and attention to expiration dates is particularly important. Using expired medications can result in reduced potency and inadequate treatment of the herpesvirus infection.

Safe handling and disposal of famciclovir protects household members and the environment. The medication should be stored in a location inaccessible to children and other pets to prevent accidental ingestion. Pregnant women should minimize handling of famciclovir tablets and should not handle crushed tablets or liquid formulations due to potential absorption through the skin. If tablets need to be cut to achieve the correct dose, this should be done carefully, and any powder should be cleaned up promptly. Unused medication should be disposed of properly rather than discarded with regular household trash. Many veterinary clinics and pharmacies participate in medication take-back programs that provide environmentally responsible disposal options. If such programs are unavailable, famciclovir can be mixed with an undesirable substance such as coffee grounds or cat litter, placed in a sealed container, and disposed of with regular trash.

Famciclovir is generally well-tolerated across all cat breeds when used appropriately for the treatment of feline herpesvirus infections. The medication's oral administration and systemic distribution mean that breed-related variations in facial anatomy or eye structure, which can influence topical medication use, have minimal impact on famciclovir therapy. However, certain breed characteristics and predispositions may influence disease presentation, treatment decisions, and monitoring approaches. Veterinarians consider each cat as an individual while remaining aware of breed-related factors that could affect herpesvirus disease or medication response.

Brachycephalic breeds such as Persians, Himalayans, and Exotic Shorthairs may be predisposed to more severe or persistent herpesvirus disease due to their shortened facial anatomy. These breeds often have pre-existing ocular surface abnormalities including tear drainage problems and corneal exposure that can complicate herpetic eye disease. Additionally, chronic respiratory issues associated with brachycephalic airway anatomy may be exacerbated when herpesvirus respiratory infection occurs. Famciclovir can be particularly valuable for these breeds because its systemic activity addresses both ocular and respiratory manifestations simultaneously. Owners of brachycephalic cats should understand that their pets may require longer treatment courses or more frequent interventions for herpesvirus disease.

Breed size considerations in cats, while less variable than in dogs, can still influence medication dosing and administration. Large breed cats such as Maine Coons may require higher total doses to achieve therapeutic drug concentrations, potentially necessitating multiple tablets per dose. This can increase medication cost and may present administration challenges if the cat resists taking pills. Conversely, very small cats or those significantly underweight require careful dose calculation to avoid relative overdosing. Using appropriately sized tablet strengths or compounded formulations can help ensure accurate dosing for cats at the extremes of the size spectrum. Owners should ensure their cat's weight is accurately measured at the veterinary clinic.

Age-related considerations apply across all breeds and significantly influence famciclovir therapy decisions. Kittens are highly susceptible to severe herpesvirus infections due to their immature immune systems, and early appropriate treatment can prevent serious complications. Famciclovir has been used successfully in juvenile cats, though dosing may require adjustment based on the kitten's developmental stage and weight. Senior cats of any breed commonly have concurrent health conditions, particularly chronic kidney disease, that influence medication selection and monitoring requirements. Older cats receiving famciclovir should have baseline kidney function assessed and may benefit from follow-up blood work during extended treatment courses. The veterinarian will develop an age-appropriate treatment plan that balances antiviral therapy benefits with safety considerations for each patient's life stage.

Several other antiviral medications may be considered as alternatives or adjuncts to famciclovir for treating feline herpesvirus infections. Within the oral systemic antiviral category, famciclovir remains the primary choice for cats due to its favorable safety profile. Valacyclovir, the prodrug of acyclovir that is commonly used in humans, is absolutely contraindicated in cats because it causes severe and potentially fatal toxicity affecting the kidneys, liver, and bone marrow. Cat owners should never give human valacyclovir or acyclovir to their cats under any circumstances. This important safety distinction makes famciclovir the default systemic antiviral option when oral medication is needed for feline herpesvirus disease.

Topical ophthalmic antivirals represent an important alternative category for cats with primarily ocular herpesvirus disease. Cidofovir 0.5 percent ophthalmic solution offers excellent antiviral activity with the convenience of twice-daily dosing. Trifluridine and idoxuridine are older topical antivirals that require more frequent administration (four to six times daily) but remain effective options. Ganciclovir ophthalmic gel is another topical choice that has shown variable results in clinical studies. These topical medications provide high local drug concentrations at the eye surface but cannot address respiratory or dermatologic manifestations of herpesvirus disease. Veterinarians may prescribe topical antivirals alone for mild ocular disease or in combination with oral famciclovir for comprehensive treatment of cats with severe or multi-system involvement.

Complementary therapies often accompany antiviral treatment as part of comprehensive herpesvirus management in cats. Lysine supplementation has been historically recommended based on theoretical mechanisms of antiviral activity, though recent research has questioned its clinical efficacy. Regardless, some veterinarians continue to include lysine as a low-risk supportive measure. Cats with secondary bacterial infections affecting the eyes or respiratory tract may require concurrent antibiotic therapy. Doxycycline is commonly prescribed for cats with upper respiratory disease to address potential bacterial copathogens such as Chlamydia felis and Bordetella bronchiseptica. Supportive care including humidification, nutritional support, and gentle cleaning of ocular and nasal discharge helps cats feel more comfortable during active disease. The veterinarian will develop an individualized treatment plan incorporating antiviral medication with appropriate supportive measures, and owners should never substitute medications or modify treatment protocols without professional guidance.